Advances in Lung Cancer Evaluation and Management

e-Supplement 1 to Volume 79
May 2012

www.ccjm.org/content/79/e-Suppl_1.toc

Supplement Editors

Nathan Pennell, MD, PhD
Peter Mazzone, MD
Cleveland Clinic

Contents

Lung cancer screening: Examining the issues e-S1
Peter Mazzone

Treatment implications of the new lung cancer staging system e-S7
Cristina P. Rodriguez

Bronchoscopy and endobronchial ultrasound for diagnosis and staging of lung cancer e-S11
Francisco Aécio Almeida

Preoperative evaluation of the lung resection candidate e-S17
Peter Mazzone

Video-assisted thoracoscopic surgery for the treatment of lung cancer e-S23
Sudish Murthy

Stereotactic body radiotherapy for stage I non–small cell lung cancer e-S26
Kevin Stephans

Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen? e-S32
Gregory M.M. Videtic

The role of surgery for locally advanced non–small cell lung cancer e-S38
David P. Mason

The role of adjuvant chemotherapy in early-stage and locally advanced non–small cell lung cancer e-S42
Marc Shapiro

Selection of chemotherapy for patients with advanced non–small cell lung cancer e-S46
Nathan A. Pennell

The emerging role of palliative medicine in the treatment of lung cancer patients e-S51
Mellar P. Davis

Personalized targeted therapy in advanced non–small cell lung cancer e-S56
Patrick C. Ma

This supplement is based on the proceedings of a symposium convened in Cleveland, Ohio, on April 30, 2011, by the Cleveland Clinic Center for Continuing Education and the Cleveland Clinic Journal of Medicine. *The transcripts of presentations were formatted and edited by* Cleveland Clinic Journal of Medicine *staff for clarity and conciseness and were then reviewed, revised, and approved by the authors.*

Topics and editors for supplements to the *Cleveland Clinic Journal of Medicine* are determined by the *Journal*'s editor-in-chief and staff. Supplement editors are chosen for their expertise in the topics discussed and are responsible for the scientific quality of supplements, including the review process. The *Journal* ensures that supplement editors and authors fully disclose any relationships with industry, including the supplement underwriter. For full guidelines on grant-supported supplements to the *Journal*, go to **www.ccjm.org/site/misc/Supplement_Guidelines.pdf**.

Copyright © 2012 The Cleveland Clinic Foundation. All rights reserved.

The statements and opinions expressed in this supplement to the *Cleveland Clinic Journal of Medicine* are those of the authors and not necessarily of The Cleveland Clinic Foundation, its Board of Trustees, Pfizer, Inc., Genentech, Inc., or Merck & Co. They do not necessarily represent formal practice guidelines in effect at Cleveland Clinic.

The *Cleveland Clinic Journal of Medicine* [ISSN 0891-1150 (print), ISSN 1939-2869 (online)] is published 12 times yearly by The Cleveland Clinic Foundation.

Subscription rates: U.S. and possessions: personal $120; institutional $148; single copy/back issue $20. Foreign: $165; single copy/back issue $20. Institutional (multiple-reader) rate applies to libraries, schools, hospitals, and federal, commercial, and private organizations. Individual subscriptions must be in the names of and paid by individuals.

Postmaster address changes: *Cleveland Clinic Journal of Medicine*, 1950 Richmond Road, TR4-04, Lyndhurst, OH 44124. Subscription orders, editorial, reprint, and production offices (same address): 216-444-2661 (phone); 216-444-9385 (fax); ccjm@ccf.org (e-mail); www.ccjm.org (Web).

Printed in USA.